RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis

Journal of Clinical Investigation

Volumn 126, Issue 8, 2016, Pages 2919-2932

  Lesina, Marina ^a   Wörmann, Sonja Maria ^a   Morton, Jennifer ^b   Diakopoulos, Kalliope Nina ^a   Korneeva, Olga ^a   Wimmer, Margit ^a   Einwächter, Henrik ^a   Sperveslage, Jan ^c   Demir, Ihsan Ekin ^a   Kehl, Timo ^d   Saur, Dieter ^a   Sipos, Bence ^e   Heikenwälder, Mathias ^d,f   Steiner, Jörg Manfred ^a,g   Wang, Timothy Cragin ^h   Sansom, Owen J ^b   Schmid, Roland Michael ^a   Algül, Hana ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g TEXAS A AND M UNIVERSITY   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; I KAPPA B ALPHA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C JUN; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; CXCL1 PROTEIN, MOUSE; MESSENGER RNA; RAS PROTEIN; RELA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL ONCOGENE; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; IMMUNOSURVEILLANCE; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SENESCENCE; TUMOR GROWTH; ANIMAL; CELL AGING; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; ONCOGENE; ONCOGENE RAS; PANCREAS CARCINOMA; PANCREAS TUMOR; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; CELL AGING; CHEMOKINE CXCL1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; MALE; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PANCREATIC NEOPLASMS; RAS PROTEINS; RECEPTORS, INTERLEUKIN-8B; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84987806939     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI86477     Document Type: Article

References (58)

1. Ling J, et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(1):105-120.
2. Maier HJ, Wagner M, Schips TG, Salem HH, Baumann B, Wirth T. Requirement of NEMO/ IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas. Oncogene. 2013;32(21):2690-2695.
3. Maniati E, et al. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest. 2011;121(12):4685-4699.
4. Bassères DS, Ebbs A, Levantini E, Baldwin AS. Requirement of the NF-kappaB subunit p65/ RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 2010;70(9):3537-3546.
5. Xia Y, et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol. 2012;14(3):257-265.
6. Meylan E, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature. 2009;462(7269):104-107.
7. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121(7):977-990.
8. Luedde T, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11(2):119-132.
9. Dajee M, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003;421(6923):639-643.
10. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012;12(2):121-132.
11. Chien Y, et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 2011;25(20):2125-2136.
12. Caldwell ME, et al. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene. 2012;31(12):1599-1608.
13. Collado M, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005;436(7051):642.
14. Guerra C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011;19(6):728-739.
15. Lee KE, Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell. 2010;18(5):448-458.
16. Morton JP, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(1):246-251.
17. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130(2):223-233.
18. Moir JA, White SA, Mann J. Arrested development and the great escape-The role of cellular senescence in pancreatic cancer. Int J Biochem Cell Biol. 2014;57:142-148.
19. Algül H, et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Invest. 2007;117(6):1490-1501.
20. Kang TW, et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature. 2011;479(7374):547-551.
21. Krizhanovsky V, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657-667.
22. Hu C, Sun L, Hu Y, Lu D, Wang H, Tang S. Functional characterization of the NF-kappaB binding site in the human NOD2 promoter. Cell Mol Immunol. 2010;7(4):288-295.
23. Asfaha S, et al. Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology. 2013;144(1):155-166.
24. Schwitalla S, et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 2013;23(1):93-106.
25. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685-705.
26. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123(3):966-972.
27. Jing H, et al. Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 2011;25(20):2137-2146.
28. Maeda S, et al. IκB kinaseβ/nuclear factor-κB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology. 2009;50(6):1851-1860.
29. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547-556.
30. Singh SK, Ellenrieder V. Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics. Gut. 2013;62(9):1364-1372.
31. Acosta JC, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):978-990.
32. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118.
33. Coppé JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853-2868.
34. Pérez-Mancera PA, Young AR, Narita M. Inside and out: the activities of senescence in cancer. Nat Rev Cancer. 2014;14(8):547-558.
35. Young AR, Narita M. SASP reflects senescence. EMBO Rep. 2009;10(3):228-230.
36. Lujambio A, et al. Non-cell-autonomous tumor suppression by p53. Cell. 2013;153(2):449-460.
37. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155-1166.
38. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-737.
39. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176-185.
40. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.
41. Khaled YS, Ammori BJ, Elkord E. Myeloidderived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91(8):493-502.
42. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105-115.
43. Highfill SL, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra67.
44. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72(11):1622-1631.
45. Acosta JC, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133(6):1006-1018.
46. Lesina M, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456-469.
47. Quante M, et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;21(1):36-51.
48. Matsuo Y, et al. CXCL8/IL-8 and CXCL12/ SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 2009;124(4):853-861.
49. Ijichi H, et al. Inhibiting Cxcr2 disrupts tumorstromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest. 2011;121(10):4106-4117.
50. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. CXCR2-expressing myeloidderived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013;24(5):631-644.
51. Burgess DJ. Senescence. NF-κB shows its beneficial side. Nat Rev Cancer. 2011;11(12):832-833.
52. Klein U, Ghosh S. The two faces of NF-κB signaling in cancer development and therapy. Cancer Cell. 2011;20(5):556-558.
53. Perkins ND. NF-κB: tumor promoter or suppressor? Trends Cell Biol. 2004;14(2):64-69.
54. Tergaonkar V, Perkins ND. p53 and NF-κB crosstalk: IKKα tips the balance. Mol Cell. 2007;26(2):158-159.
55. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-450.
56. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14(8):994-1004.
57. Nakhai H, et al. Ptf1a is essential for the differentiation of GABAergic and glycinergic amacrine cells and horizontal cells in the mouse retina. Development. 2007;134(6):1151-1160.
58. Aguirre AJ, et al. Activated Kras and Ink4a/ Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-3126.